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Abstract Preparation of amniotic membrane (AM)
by air drying method followed by radiation sterili-
zation is simple and valuable approach; sterility and
quality of the final AM product are depending on the
quality management system at the tissue bank.
Validation and substantiation of radiation steriliza-
tion dose (RSD) for tissue allografts is an essential
step for the development and validation of the
standard operating procedures (SOP). Application
of SOP is perfectly relying on trained staff. Skills
differences among personnel involved in AM prep-
aration could have an effect on microbiological
quality of the finished product and subsequently on
the RSD required. AM were processed by four
different couples of the tissue bank technicians. The
AM grafts were randomly selected and subjected to
bioburden test to validate and substantiate the
25 kGy RSD. Bioburden test for AM grafts were
also useful to evaluate the skill of the tissue bank
technicians and thus, to validate the current SOP for
air dried AM. Moreover, the effect of placental
source on bioburden counts on AM grafts was
assessed. Substantiation of the 25 kGy RSD at a
sterility assurance level of 10-1, and sample item
portion = 1, was carried out using Method VDmax
25 of
the International Organization for Standardization,
document no. 11137-2 (ISO in Sterilization of
healthcare products—radiation—part 2: establishing
the sterilization dose, Method VDmax—substantia-
tion of 25 kGy or 15 kGy as the sterilization dose,
International Standard Organization, 2006). The
results showed that there were no significant differ-
ences in the bioburdens of the four batches
(a = 1 %), this means no significant differences in
the skill of the four couples of the tissue bank
technicians in terms of their ability to process AM
according to the air dried AM SOP. The 25 kGy RSD
was validated and substantiated as a valid steriliza-
tion dose for the AM prepared with the current
established SOP at the Biotechnology Research
Center experimental tissue bank. The donor’s type
of delivery, normal or caesarean, showed no signif-
icant effect on the levels of microbial counts on the
tested AMs (a = 1 %).
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Introduction
Tissue banking activity and radiation sterilization of
tissue allografts has been expanding to many devel-
oping countries in the new millennium. The typical
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operation of a tissue bank to produce sterile tissue
allografts necessitates the adoption of any of the tissue
banking standards, i.e. American Association of
Tissue Banks AATB (AATB 2002), European Asso-
ciation of Tissue Banks (EATB), (EATB 1995),
International Atomic Energy Agency (IAEA) stan-
dards (IAEA 2003), as well as International Standard
Organization ISO documents for radiation sterilization
dose (RSD) selection (ISO 11137-1 2006).The con-
firmation of sterility, safety and efficiency of tissue
allografts together with the dose setting and choice of
the RSD are the responsibility of the tissue banker
(Morales Pedraza et al. 2012).
Human amniotic membranes (AM) is obtained from
placentae of healthy mothers upon delivery; it is readily
available, cost effective and contains a variety of growth
factors that are required for fast healing of burns, ulcers
of skin and eye surface. The recent wide use of AM
especially in burn and ophthalmology practice imposes
an obligation on tissue banks to ensure quality of their
product materials.
Our staff gained experience in the past years
through the IAEA technical assistance by partici-
pating in the IAEA regional and interregional tissue
banking activities, namely fellowship programmes,
training courses, workshops etc. A project for
processing of air dried AM was then proposed in
early 1999 in Tajoura Nuclear Research Center
(TNRC). Later on, in 2002, a research tissue bank is
started at the Human Tissues Department at the
Biotechnology Research Center (BTRC). Early
batches of AM grafts were utilized in selected burn
cases in 2003 (Marsit et al. 2006). Interruptions in
the procurement and processing had delayed the
extensive use of amnion untill 2009 when the
project was revived. During the bank set up phase,
AM was prepared by air drying method followed by
radiation sterilization. This simple and valuable
approach was easily adopted by the experimental
tissue banks especially in developing countries;
while sterility and quality of the final AM graft
were ensured through the quality system established
by the tissue bank. However, at international level,
distinct developments have been taking place in
recent years to standardize the processing proce-
dures and facilitate the selection of the terminal
RSD for tissue allografts (Morales Pedraza et al.
2012).The use of 25 kGy as a terminal sterilization
dose for tissue allografts has been practiced for
several decades since its first introduced in 1950s.
The 25 kGy dose is also recommended by the IAEA
Standards for Tissue Banks (IAEA 2003) and the
AATB Standards (AATB 2002) as the minimum
dose for bacterial sterilization, till date it is still
acceptable and usable in many tissue banks (Nguyen
et al. 2007).
To ensure safety and quality of tissue grafts to be used
in clinical applications, retraining is mandatory for
personnel involved in any parts of the tissue banking
professional activity, especially when there is a need for
change in procedures or new scientific knowledge
(Kaminski et al. 2013). At the BTRC experimental
tissue bank, the standard operating procedures SOP
established for processing air dried AM was amended in
line with the improvement of the tissue bank capabilities
over time, likewise, tissue bank processing staff were
retrained in the aseptic technique and processing skills.
In addition, the skill of the tissue bank staff is among the
factors that might affect the bioburden of the prepared
amniotic membrane grafts, thus, control of contamina-
tion sources, strictly follow processing procedures and
validation of the product samples are crucial and subject
to continuous improvement.
The tissue banking standards published by autho-
rized organizations and associations such as ISO,
AATB, obliging their member tissue banks to
standardize and validate the processing procedures
of the produced tissues, and every individual tissue
bank is obliged to create their own SOP starting from
donor screening and consent till the final step of
tissue distribution. In addition, tissue banking experts
urge on performing RSD validation using the IAEA
code of practice (IAEA 2007) or any of the
appropriate ISO documents at least four times a year
in order to ensure sterility of the processed tissue
allografts, thereof, substantiation of the RSD for air
dried AM is essential. The ISO 11137-2 VDmax
25
method is considered suitable for AM grafts, as this
method is formulated for small batches of biological
products (Yusof 2007).
The aim of this work was to validate and
substantiate the 25 kGy RSD for air dried AM
prepared at the BTRC tissue bank, and to evaluate
the differences in microbiological quality of the AM
grafts produced by different tissue bank workers.
The effect of the types of delivery, either normal or
caesarean, on the bioburden level was also
investigated.
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Materials and methods
Human AM preparation procedures
Human amniotic membrane was prepared according to
the procedure described in the IAEA Multimedia
Distance Learning Package on Tissue Banking, (IAEA
1997) with modification. The SOP was validated by the
BTRC experimental tissue bank. More than 235 AM
grafts were produced from 91 placentae in the period
between January 2009 and November 2010. The AM
processing were carried out by four different couples of
tissue bank workers; the participating technicians have
similar academic background and training levels.
Briefly, human placentas were collected from
Maternity Department of Ali Omar Asskar Hospital.
The mother donors were screened negative for HIV,
HBV and HCV. The adopted processing procedures for
air dried amnion were comprised of wet and dry
processing stages (IAEA 1997). It is advised to separate
processes involving the use of washing solutions and
raw tissue allografts from those having adequately
clean handling such as cutting, packaging and labeling,
for the purpose of minimizing contamination. Each
placenta was processed separately, pooling of placentae
or AMs together is forbidden.
Wet processing
At the tissue bank, the AM was peeled off from the
placenta; the membranes were thoroughly washed in
cold running water till they were free of blood clots.
Then, the membranes were washed subsequently three
times in sterile saline solution followed by a single
wash in 0.05 % sodium hypochlorite solution and
finally rinsed three times with sterile distilled water.
Washing was done using electrical shaker (GFL 3006,
Germany) in screw capped media bottles (DURAN
10011391, Duran Gm bH, Germany) containing
300 ml each; every individual washing/shaking lasted
for 15 min. Sterile long forceps were used to transfer
AM to washing bottles.
Dry processing
Subsequently, inside the Class II safety cabinet (HER-
ASAFE KS9, Thermo Scientific, Germany), the mem-
branes were spread over sterile cotton gauze (Winner
industries, Shenzhen Co., LTD, China) on a sterile glass
plate and sterile saline was used to prevent amnion
sticking to the glass plate. The gauze with amnion was
then mounted onto sterilized dual circular wooden
frames (Ø = 16 cm), ‘‘the ones used in textile stitching
crafts’’ (Fig. 1a) and air dried in biosafety cabinet for
overnight (C18 h), then, the membranes were cut,
trimmed and packed in inner polyethylene packs
(Fig. 1b, c) which were enveloped in pre-autoclaved
self-seal sterilization pouches (Sigma medical supplies
corp., Taiwan). The AM grafts envelopes were then
labeled, heat sealed using (ALLPAX PT-MJ-4 DS, Gm
bH&Co. KG, Germany) machine and stored at room
temperature, small pieces remained after cutting was
used as quality control samples.
Validation and substantiation of 25 kGy RSD
Obtaining AM samples
The selection of AM graft samples for bioburden test
and verification of sterilization dose was done ran-
domly from the stocks of the AM grafts routinely
processed during 2009–2010. The collection of 10 AM
grafts for bioburden estimation and 10 for verification
of dose would not be possible from a single placenta,
therefore only months (batches) that were having more
than 20 AMs were included in this work.
Although, this approach is not completely comply
with the standards for obtaining the samples for
bioburden and verification experiment, this modifica-
tion was unavoidable to overcome constraints set by the
standards and was vastly discussed by other authors in
previous works (Hilmy et al. 2000; Nguyen et al. 2007).
The number of placentae used to collect 20 AM product
units for every batch is shown in Table 1.
In this study, four batches (A, B, C and D) were
chosen. The AMs in each batch were prepared by
ascertained couple of technicians (two technicians/one
batch).
Bioburden estimation for validation
and substantiation of 25 kGy RSD
The bioburden experiments were conducted according
to ISO 11737-1 (2006). Bioburden estimation was
done for each of the 10 selected AM grafts of the four
AM batches. Extraction of microbes from AM graft
was done by washing in 300 ml polysorbate saline
solution (0.1 % tween 80) and mechanical shaking for
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15 min, the solutions were filtered under vacuum
through a 0.45 lm pore size, 47 mm diameter sterile
cellulose nitrate membrane filters (Whatman Cat#
7187, Whatman Paper Limited, England), using
(Millipore pump, Model: WP6122050, Millipore
corp., USA), the filters were incubated onto Tryptic
Soy Agar (TSA) medium ‘‘Casein soya bean digest
agar’’ (Code# 610052 Liofilchems.r.l. Biotechnology
products, Italy) at 34 C using (FIRLABO.sa, type:
P1407B, France) incubator, the colony forming units
(cfu) were counted and selected colonies were sub-
cultured, morphologically and microscopically iden-
tified using gram’s stain and stocked in agar tubes at




25 Method of the ISO 11137-2 (2006),
the dose verification was performed for each of the four
batches A, B, C and D. The procedure requires another
ten AM grafts, nearly the same size as those used in
bioburden estimation. The whole sample was used in this
destructive test, thus the sample item portion (SIP) = 1.
Ten AM grafts resembling a single batch were irradiated
at room temperature with verification doses obtained
from Table 9 of ISO, 11137-1 (2006), for levels of
average bioburden B1,000 cfu and verification sterility
assurance level (SAL) = 10-1 (means, probability of 1
non sterile item out of 10). Irradiation of samples was
done using gamma irradiator at the National Center for
Sciences and Nuclear Techniques (CNSTN), Sedi
Thabet, Tunis-Tunisia, and Amber Perspex dosimeters
were used to measure absorbed doses by AM grafts. Each
of the ten radiation treated AM sample (SIP = 1) of each
of the four batches A-D was tested for sterility using the
recommendations in ISO 11737-2 (2006). Briefly,
autoclaved media bottles containing 300 ml Tryptic
Soy Broth (TSB) ‘‘Casein soya bean digest broth’’
(Code# 610053 Liofilchems.r.l. Biotechnologyproducts,
Italy) were used to check the sterility of amnion grafts
irradiated at the verification doses; AM samples were
transferred under aseptic control to the TSB media
bottles, the bottles containing amnion samples were
incubated at 34 C for 14–21 days.
Results and discussion
Bioburden estimation
Bioburden is a good measure for monitoring micro-
biological quality of the final products of the routine
processing of AM (Yusof and Hassan 2007) and as a
Fig. 1 a Amniotic membrane stretched over sterile gauze and
tightened into sterilized dual circular wooden frame. b,
c Amniotic membrane graft cutting, trimming and packaging
in inner polyethylene packs
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reliable indicator on the level of hygienic conditions at
the AM processing site. Bioburden variations might
occur due to differences in AM preparation and
handling skills of the working staff. AM processing
must be properly carried out by staff who have
adequate training in clean or aseptic processing.
Table 1 Placentae sources,
bioburden counts and average
grafts produced per placenta of
the four batches of amniotic
























































87 CS 3.6 14 7.8 ± 7.6
86 N 6
88 CS 0
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Validation and substantiation of RSD for AM is an
essential step for establishment of an SOP. Based on the
requirement set by the ISO 11137-1 (2006), it was
possible to validate and substantiate the RSD using
Method VDmax
25 , as all the four batches tested had
bioburden counts B1,000 cfu/graft. The average num-
ber of AM grafts gained from an individual processed
membrane was 3.28 AM grafts/placenta with a range of
2.6–3.6 The overall average size of the AM grafts was
99.0 cm2. List of placenta source and bioburden counts
is illustrated in Table 1. For bioburden estimation, each
AM graft was used entirely (SIP = 1); thereof, appli-
cation of the correction factor for bioburden counts is
not a strict requirement in this work. The average
bioburden for the batches A, B, C and D were 3.9, 13.9,
46.8 and 7.8 cfu/AM graft respectively.
Statistical analysis of bioburden results as shown in
Table 1 using two way ANOVA indicated no signif-
icant differences (a = 1 %) in bioburden of the AM
prepared by four different couples of the tissue bank
technicians, meaning that all of the technicians have
similar skills and were able to follow the written SOP
for processing of air dried AM in consistent manner.
Processing of air dried AM was initially learnt by trial
and error; upon several trials the errors became
minimum and the practice became perfect. The skills
in preparation techniques especially AM dissection,
cleaning and aseptic packaging as well as bioburden
determination using membrane filtration method are
like any other skill, can be improved through practice.
The overall average bioburden of the four batches (40
AM grafts) tested in this work was 18.35 cfu (Table 1)
which is much lower than that processed in the early
trials of AM preparations at the BTRC experimental
tissue bank in 2004 with average cfu of *103–104)
(Marsit et al. 2006).
To ensure safety and quality of the tissue grafts for
use in clinical applications, continuous training is
mandatory for personnel involved in any part of the
tissue banking activity, especially when there is a need
for change in procedures or new scientific knowledge
(Kaminski et al. 2013). Most of the improvements were
attributed to the review of the SOP e.g. changing the
disinfecting treatment with 70 % alcohol to 0.05 %
sodium hypochlorite solution, furthermore, workers
recruited as permanent tissue bank staff have more
skills than those temporarily assigned with different
procedures, and their experience were impacted pos-
itively on the overall activity.
Additionally, considerable checkings on the pro-
cessing methodology such as sterile gloving, gowning
and personnel movements and work behavior are done
in parallel with continuous monitoring and assess-
ment, additionally, aseptic handling of AM, especially
during cutting and packing inside the safety cabinet
must be carried out in a slow and purposefully manner
which has led to a distinct effect in lowering the
bioburden counts of the recently produced air dried
AM batches. Handling of AM grafts after drying
should be strictly done using sterile tools.
However, knowing the potential sources of contam-
ination is a step towards avoiding it. When personnel is
expected to be a potential source of contamination
during processing, then the mishandling intervention of
them has to be minimized, hence, the risk of microbi-
ological contamination of amnion graft will be mini-
mized through aseptic technique.
In general, the quality of our AM grafts in terms of
bioburden is relatively low when compared to similar
AM grafts produced at recognized or regional exper-
imental tissue banks; in Indonesia, for example, the
yearly average bioburden for lyophilized AMs
Table 1 continued
AM Amniotic membrane, Av.
Average, N Normal delivery
CS Caesarean delivery, cfu
colony forming unit, SD
standard deviation
* Placenta numbers are the



















Overall average cfu 18.35
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produced at Batan Research Tissue Bank (BRTB) was
120 cfu in 1997 and decreased to 57 cfu in 1998/prod-
uct unit (Hilmy et al. 2000), whereas, in Malaysia, the
bioburden counts on AM grafts were improved over
years ranging from 85.2 in 1990 to 2.7 cfu/amnion
graft in 1996 (Yusof and Hassan 2007; Yusof et al.
2007) whilst, a study at the tissue banking laboratory
of Nuclear Research Centre of Algiers-Algeria,
showed that the average bioburden from 10 lyophi-
lized AM samples was 572 cfu (Djefal et al. 2007).
Validation and substantiation of 25 kGy radiation
sterilization dose
Obtaining VDmax
25 and performing verification dose
experiment
Following the ISO 11137-2 VDmax
25 method, the dose
verification was performed for each of the four batches
A, B, C and D, therefore, another ten AM, SIP = 1
(from the matching placenta used in bioburden
estimation and were nearly the same sizes), were
irradiated at room temperature with verification doses
of 6.1, 7.0, 8.2 and 6.9 kGy respectively. Verification
doses were again obtained from Table 9 of the
foresaid ISO document (ISO 11137-2 2006) based
on their bioburden counts determined earlier accord-
ing to ISO 11737-1 (2006), i.e. the corresponding
average bioburden for batches A, B, C and D were 3.9,
13.9, 46.8 and 7.8 cfu/AM graft respectively.
The results of the dose verification sterility test after
14 days incubation period at 34 C, showed that the
verification was accepted for all the batches A, B, C
and D, as none of the test had two or more positive
results (Table 2). This result demonstrated that quality
system applied at the BTRC tissue bank is capable of
producing AM grafts with acceptable levels of
bioburden (e.g. 18.35 cfu), which is far less than the
limit set by the ISO document no. 11137-2 (2006)
which is \1,000 cfu. Therefore the 25 kGy RSD is
substantiated as the reliable dose for sterilization of
AM prepared at the BTRC tissue bank.
Effect of placental source
For bioburden estimation, the term ‘‘batch’’ used here
resembles a number of placentae processed within a
single month, including placentae from both normal
and caesarean delivery. The type of delivery was not
controlled in our experiment, however, to compare
both placentae types from the bioburden point of view,
the average bioburden was calculated for each group
of AM used in this work and statistically analyzed.
From the 40 AM grafts used for bioburden estima-
tion for the dose verification purpose of the four
processing batches, 36 AM grafts obtained from 18
normal and 18 caesarean deliveries were selected for
the comparison. To eliminate errors, three amniotic
membranes with comparably higher bioburden counts
that originated from one caesarean placenta (No.36)
were excluded from these calculations, as it was
revealed being coincidently contaminated by fungal
airborne spores during packaging.
The average bioburden results of AM grafts prepared
from normal and caesarean placentae were
9.6 cfu ± 7.4/AM graft (range 1–26 cfu) and
8.9 cfu ± 6.3/AM graft (range 0–21 cfu) respectively
(Table 3). Statistical analysis using two way ANOVA
shows no significant differences (a = 1 %) between the
two sources of placenta (normal and caesarian section),
and any differences were due to chance or coincidence,
P value\0.01 was considered statistically significant.
Despite that the bioburden from the four tested
batches (40 AM grafts) which result in overall average
bioburden of 18.35 cfu/AM graft, is low; the risk from
bacterial contamination of vaginal delivery obtained
placenta, is higher than that from caesarian delivery
source; even though, contamination of placenta is
unavoidable in either normal or caesarian delivery
types, however, the bacterial species associated with
vaginal delivery are pathogenic and arising from
different sources, i.e., vagina, gut, skin and mouth
flora (Adds et al. 2001). In addition, contamination by
personnel mishandling during processing is less risky
than vaginal delivery contamination, unless otherwise
they have insufficient skills that helps in prevent cross
contamination, or transmitting radiation resistant
bacterial spores from working environment.
Air dried AM attached to sterile gauze is intended
to be used for skin burns; therefore, massive quantities
are required, hence, natural deliveries are abundantly
available with less processing costs. Adds et. al.
showed that the all 21 samples collected in his study,
both caesarean and vaginal, were contaminated with
22 different bacterial species. On the other hand, a
verified gamma radiation sterilization dose is suffi-
cient to eliminate bacterial contamination in the range
specified by the standards,\1,000 cfu.
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Conclusion
Regardless of type of delivery, if placenta is properly
handled and AM is prepared according to SOP
established for air dried AM, the bioburden counts
will be very low, and hence, the 25 kGy radiation dose
will be easily substantiated using VDmax
25 approach,
providing that the product average bioburden should
be below 1,000 cfu per product unit.
In addition, the low bioburden must be maintained
and result reproducibility needs to be confirmed by
repeating the dose validation work quarterly a year as
recommended by the ISO standards. Quality and
sterility of AM do not rely only on the 25 kGy terminal
sterilization dose, an improved SOP for processing
and personnel progressive training are equally impor-
tant and would have better effects.
Although the bioburden test of AM final packed
product is a good measure to evaluate its microbio-
logical quality during routine processing in tissue
banking; however, the bioburden test is incapable to
confirm the source of contamination and could only
assume it by correlating the isolated bacterial genera
to its natural floral localization.
If AM production could be identified as a ‘‘Pro-
cess’’, then the process capability can be evaluated in a
frequent manner using statistical approaches such as
the process capability index (Cpk) using X bar/R-
Charts and Pareto analysis to set limits and to look for
process changes, thus, identifying the most possible
causes of contamination ‘‘defects’’. These require
environmental monitoring of the processing site and
tracking any changes in number and type of the
contaminants by taking air and water samples, samples
from washing solutions, swab samples from surfaces,
packing materials, used tools, placenta and end product
as well as monitoring skill of personnel involved in the
AM production.
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